title: Atopic eczema.
abstract: Atopic eczema is an itchy inflammatory skin disease with a chronic relapsing-remitting course; it has increased in prevalence in recent decades and now affects up to 25% of school-aged children in the developed world and up to 10% of adults. Recent advances in understanding the aetiology of eczema have focused interest on skin barrier dysfunction as a common precursor and pathological feature. In addition, genetically determined skin barrier dysfunction (associated with mutations in the gene encoding filaggrin) is known to predispose to multiple systemic atopic diseases. First-line treatments for atopic eczema focus on maintaining and repairing the skin barrier (emollients) and reducing inflammation (topical steroids); allergen and irritant avoidance are also important to achieve disease control. Second and third-line treatments include topical calcineurin inhibitors, ultraviolet light and systemic immunosuppressant therapies of which only ciclosporin is licenced for the treatment of atopic eczema in adults. Novel biological therapies are in phase II-III clinical trials.
authors.affiliation: Wellcome Trust senior research fellow in clinical science and honorary consultant dermatologist, Skin Research Group, Ninewells Hospital and Medical School, Dundee, UK s.j.brown@dundee.ac.uk.
authors.forename: Sara J
authors.initials: SJ
authors.lastname: Brown
mesh_terms: D000328:Adult; D002648:Child; D003876:Dermatitis, Atopic; D004485:Eczema; D000091344:Filaggrin Proteins; D006801:Humans; D012867:Skin / Q000473:pathology
keywords: Atopic; barrier; dermatitis; eczema and filaggrin
references.citation: J Allergy Clin Immunol. 2004 May;113(5):832-6
references.pmid: 15131563
references.citation: J Invest Dermatol. 2012 Mar;132(3 Pt 2):751-62
references.pmid: 22158554
references.citation: Lancet. 2016 Jan 2;387(10013):40-52
references.pmid: 26454361
references.citation: N Engl J Med. 2005 Jun 2;352(22):2314-24
references.pmid: 15930422
references.citation: Nat Genet. 2006 Mar;38(3):337-42
references.pmid: 16444271
references.citation: N Engl J Med. 2014 Jul 10;371(2):130-9
references.pmid: 25006719
references.citation: N Engl J Med. 2011 Oct 6;365(14):1315-27
references.pmid: 21991953
references.citation: J Allergy Clin Immunol. 2013 Sep;132(3):774-774.e6
references.pmid: 23993356
references.citation: Genome Res. 2015 Oct;25(10):1514-20
references.pmid: 26430162
references.citation: J Allergy Clin Immunol. 2014 Oct;134(4):818-23
references.pmid: 25282563
references.citation: Nat Genet. 2006 Apr;38(4):441-6
references.pmid: 16550169
references.citation: Br J Dermatol. 2006 Jul;155(1):145-51
references.pmid: 16792766
references.citation: Cochrane Database Syst Rev. 2015 Jan 19;1:CD008426
references.pmid: 25598014
references.citation: Br J Dermatol. 2013 Oct;169(4):901-9
references.pmid: 23855450
references.citation: J Allergy Clin Immunol. 2015 Apr;135(4):930-935.e1
references.pmid: 25618747
references.citation: J Allergy Clin Immunol. 2009 Jun;123(6):1361-70.e7
references.pmid: 19501237
references.citation: Clin Exp Dermatol. 2015 Jun;40(4):349-54; quiz 354-5
references.pmid: 25622761
references.citation: Allergy. 2014 Jan;69(1):37-45
references.pmid: 24053642
references.citation: Genome Res. 2012 May;22(5):850-9
references.pmid: 22310478